• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Brian Orelli

Articles by Brian Orelli

New Investor, Same Science: Rib-X Relaunches as Melinta

Oct. 14, 2013
By Brian Orelli
What’s a venture capital fund to do with a promising biotech with good science that’s taken a little longer to develop than everyone would have hoped?
Read More

VC Investments in Biotech Continue Strong Trend

Oct. 2, 2013
By Brian Orelli
After an insane second quarter, funding of U.S. biotechs by venture capital cooled off a bit as the weather warmed up. (See BioWorld Today, July 2, 2013.)
Read More

Nanoviricides Steps Up To NYSE MKT Listing

Sep. 30, 2013
By Brian Orelli
Companies are going public left and right. According to BioWorld Snapshots, 29 biotechs have made initial public offerings on U.S. exchanges this year.
Read More

Perle Blazing Trails in Crowdfunding and Diabetes

Sep. 23, 2013
By Brian Orelli
The rules for crowdfunding from unaccredited investors established by the 2012 Jumpstart Our Business Startups (JOBS) Act haven’t been set by the SEC – observers expect them by the end of the year – but that hasn’t stopped Boston-based Blazefund from marching forward with its crowdfunding platform.
Read More

Afferent Targets P2X3 to Tackle Cough and Pain

Sep. 16, 2013
By Brian Orelli
The tickle you feel that makes you want to cough could be caused by the same mechanism that results in chronic pain. Afferent Pharmaceuticals Inc. execs believe they have a drug to treat both.
Read More

Gilead Strikes First in Latest Round of HCV Patent Wars

Sep. 9, 2013
By Brian Orelli
Given the billion dollar potential of Gilead Sciences Inc.’s sofosbuvir, it’s not particularly surprising that other companies would try to get a piece of the drug’s sales, claiming their patents covered the hepatitis C (HCV) drug.
Read More

Can Catabasis’ SMART Drug Help it to Play Catch Up?

Sep. 3, 2013
By Brian Orelli
Although the market to treat high cholesterol and high triglycerides is crowded with drugs, with plenty more in the later stages of clinical development, Catabasis Pharmaceuticals Inc. execs said the firm has a shot to compete despite its late start. The secret weapon: a two-pronged drug using its SMART-linker technology that can be delivered orally.
Read More

Biomotiv and Torrey Pines Co-Invest in Accelerator

Aug. 19, 2013
By Brian Orelli
Biomotiv LLC and Torrey Pines Investment Inc. have teamed up to fund early stage programs and companies.
Read More

Others Could Follow Perrigo Into Ireland for Lower Tax Bill

Aug. 12, 2013
By Brian Orelli
When Perrigo Co. announced that it was purchasing Elan Corp. plc. for $8.6 billion last month, Perrigo's relocation to Ireland to take advantage of the country's 12.5 percent corporate tax rate was cited as one of the driving forces for the transaction. (See BioWorld Today, July 30, 2013.)
Read More

Even in a Heated Market IPO Isn't for Every Biotech

Aug. 5, 2013
By Brian Orelli
With 23 U.S. biotechs going public on U.S. exchanges so far this year, compared to just 11 initial public offerings (IPOs) all of last year, the IPO window is starting to look more like an IPO bubble.
Read More
Previous 1 2 … 36 37 38 39 40 41 42 43 44 … 54 55 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe